STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Anna Sommerfeld

M.Sc. in Molecular Biology, Senior Expert in Pharma & Medtech

Anna Sommerfeld is a molecular biologist by training and has more than 25 years of experience in the pharmaceutical industry, including roles at AstraZeneca, Roche and Gilead Sciences. As the founder of Mealsizer®, she has spent the past 15 years working closely with both obesity and eating disorder care, translating research into practical solutions for better health.

LinkedIn logo
Portrait imageOrange stylized human head with colorful flowers and vines growing out from the top and back.

Anna Sommerfeld holds a Master’s degree in Molecular Biology and has more than 25 years of experience in the pharmaceutical and medtech industries, including senior roles at leading companies such as AstraZeneca, Roche and Gilead Sciences. She has extensive experience working across therapeutic areas including infectious diseases, cardiometabolic conditions, CNS and nutrition, collaborating with both medical and commercial teams to translate scientific evidence into practice and making complex science accessible through clear communication. Anna is also the founder of Mealsizer®, an evidence-based portion control and nutrition tool, and for the past 15 years she has worked closely with obesity and eating disorder care, promoting healthy eating habits and nutritional interventions

Articles by

Anna Sommerfeld

Bar chart showing percentages of patients remaining in treatment over time: 100% at month 0, 84% at 6 months, 69% at 12 months, 61% at 18 months, and 60% at 24 months.
Science and publications

High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍

This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%1-4. After 2 years*, 60% of patients were still in treatment.

BMI graph showing weight loss progression over 18 months with phases of anamnesis, onboarding, structured follow-up, sustained weight loss, and goal weight reached, alongside a Yazen model team structure including doctor, psychologist, physiotherapist, dietitian, and Yazen coach with e-learning modules.
Science and publications

The Yazen Model - Modern Obesity Treatment Given Via a Digital Care Model. A Descriptive Analysis

The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.

Body Mass Index scale with categories Normal, Overweight, Obese, Severely Obese, and Morbidly Obese, indicator pointing to Normal range.
Health and lifestyle

Beyond BMI: The Lancet Diabetes & Endocrinology Commission's innovative definition of Clinical Obesity

Lancet Diabetes & Endocrinology Commission redefinesobesity beyondlimitations of traditional BMI metrics

‍

Line graph showing weight decrease for men and women over 6 months, with listed health markers checked.
Science and publications

Examining the effectiveness of a new digital care model on weight loss for people living with obesity

This real-world evaluation of more than 2,600 patients in Sweden showed that Yazen’s comprehensive digital obesity care model achieved 12.6% weight loss after 6 months, alongside significant improvements in cardiometabolic health markers. The model combines GLP-1 treatment, lifestyle intervention, and continuous multidisciplinary support through a digital platform designed for long-term obesity care.

Nutrition

Mealsizer® during weight loss with medication (such as GLP-1, for eg. Ozempic, Wegovy or Mounjaro)